asianprimenews
Breaking News
Breaking NewsGeneralPublic Interest

Where Farming Becomes the Future: Here Are 5 Reasons Why Amazon MX Player’s Mitti Deserves a Spot on Your Watchlist

by asianprimenews0426

Mumbai, India- 10th July 2025: Amazon MX Player, Amazon’s free video streaming service, recently unveiled Mitti— a deeply moving and inspirational drama that traces the emotional and entrepreneurial journey of Raghav, a successful urban executive who returns to his native village, Dol Chappra, after the sudden passing of his grandfather. What begins as an obligatory visit soon unfolds into a soul-searching journey—one that redefines success, identity, and belonging.. Inspired by real-life stories of young professionals transforming their hometowns, Mitti positions modern farming as more than tradition, becoming a path to new-age entrepreneurship. Here’s why this deeply rooted series deserves a spot on your watchlist:

• Redefines what success looks like: In a world that celebrates boardrooms and big cities, Mitti gently reminds us that success can also be found in muddy boots, ancestral land, and impact that lasts beyond applause. For Raghav, returning to his ancestral village is not a step backward—it’s a leap into authenticity. As he reconnects with the land, his community, and his grandfather’s forgotten legacy, he discovers that true success is rooted in purpose, people, and personal truth. Mitti reminds us that impact isn’t always measured in applause—it’s felt in the soil beneath your feet.

• Inspired by real-life stories that hit home: What makes Mitti feel so authentic is that it echoes stories we’ve seen or perhaps lived. Across India, countless young professionals are choosing to return to their hometowns, not out of nostalgia, but out of ambition to create change. The series draws inspiration from real-life stories of individuals who turned their backs on corporate comforts to bring dignity, innovation, and opportunity back to their villages. It’s fiction, yes— but grounded in truth. And that truth lingers.

• A fresh take on farming as new-age entrepreneurship: Through Raghav’s transition into polyhouse farming, the series showcases how traditional agricultural practices can evolve with modern thinking. It breaks outdated stereotypes around rural life and instead positions farming as a smart, scalable, and sustainable enterprise. Whether it’s leveraging agri-tech or building local ecosystems, Mitti repositions the kisan as an innovator, someone who’s not just growing crops, but a future.

• Relatable characters with real emotional weight: Led by Ishwak Singh, who brings layered vulnerability to Raghav, and Shruti Sharma as Kratika—a powerful, grounded force of nature, Mitti thrives on its emotionally rich characters. With compelling performances by Diksha Juneja, Yogendra Tiku, and Alka Amin, the series feels intimate and familiar. These aren’t just characters, they are reflections of people we know— a mentor, a confidante, a reminder of who we were or who we could be.

• Watch for free: No subscriptions. No trials. No hidden fees. Mitti is now available for free on Amazon MX Player, the Amazon Shopping App, Fire TV, and Prime Video. Whether you’re on your commute, lounging at home, or sneaking in an episode on your lunch break, this slice-of-life drama is just a tap away.

Experience a grounded and heartfelt story with Mitti, now streaming exclusively on Amazon MX Player, for free, available through its own app, on the Amazon shopping app, Prime Video, Fire TV, Smart TVs, and Airtel Xtreme.

XXX
About Amazon MX Player
Amazon MX Player is India’s leading free, premium, ad-supported entertainment service. It offers a diverse range of award-winning web series, reality shows, popular international shows and a massive movie library across multiple genres. With a strong focus on original content, Amazon MX Player has launched some of the largest shows in India, which includes Ek Badnaam Aashram, Campus Diaries, Jamnapaar, Half CA, Bhaukaal, Raktanchal, Dehati Ladke, Who’s your Gynac, Sixer, Hip Hop India, Hunter – Tootega Nahi Todega and more. Amazon MX Player also offers a rich selection of international content dubbed in Hindi, Tamil and Telugu under MX Vdesi, featuring popular shows like What’s Wrong With Secretary Kim?, Daydreamer, Gangnam Beauty, My Girlfriend Is An Alien, Put Your Head On My Shoulder, Our Story, and more. The service has won multiple national and international awards for its award-winning content and marketing innovations. Amazon MX Player is committed to entertain audiences with over 100 new shows through its compelling content slate spanning multiple genres catering to the taste of viewers across age groups.

About Amazon
The Amazon.in marketplace is operated by Amazon Seller Services Private Ltd, an affiliate of Amazon.com, Inc. (NASDAQ: AMZN). Amazon.in enables customers across India to shop for millions of products, make payments with Amazon Pay, and watch free entertainment content with Amazon MX Player.
Amazon is guided by four principles: customer obsession, passion for invention, commitment to operational excellence, and long-term thinking. Amazon Advertising, Amazon Prime, Prime Video, Fulfilment by Amazon, AWS, Kindle, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.

Share

Related posts

Why CML Isn’t a Solved Disease—And What Patients in India Need to Know* Over the past two decades, Chronic Myeloid Leukemia (CML) has undergone a transformation—from being a life-threatening condition to one that can be controlled with oral medication. Although survival rates have improved significantly, the idea of CML as a ‘manageable’ disease is now being questioned. Clinicians and patients alike are recognizing that the existing standard of care does not address the full picture—especially for India’s younger patient population, whose needs go far beyond survival. Dr Subhaprakash Sanyal Director of Haematology and BMT Services, Fortis Hospital, Mumbai, said, “There’s a common belief that starting treatment for CML means the journey is simple, but that isn’t the case. Many patients struggle to reach their treatment milestones as expected, and a significant portion need to change or stop their medication due to side effects or intolerance. In fact, about 30 to 40% discontinue their initial therapy within five years, highlighting that the standard approach doesn’t work for everyone.” CML disproportionately affects younger adults in India, where the median age of diagnosis is between 35 and 40 years—much younger than the average age of 50–60 in Western countries. At this life stage, patients are often building careers, supporting families, and planning long-term futures. In this context, treatment is no longer just about survival—it’s about maintaining energy, emotional well-being, professional productivity, and daily independence. Historically, the primary treatment goal in CML was achieving Major Molecular Response (MMR). But over the years, these goals have evolved. Today, physicians aim for deeper responses, particularly Deep Molecular Response (DMR). Achieving DMR paves the way for Treatment-Free Remission (TFR), where patients can potentially stop therapy altogether and remain in remission under medical supervision. These advanced milestones are particularly relevant to newly diagnosed patients, as reaching DMR within the first two years greatly improves the likelihood of achieving TFR down the line. Why So Many Patients Fall Short Despite clear treatment goals, a significant proportion fail to achieve MMR within the first year, and even fewer reach DMR by year two. One of the primary reasons is the impact of persistent, low-grade side effects—such as fatigue, joint pain, and gastrointestinal issues—which patients often tolerate silently but which meaningfully reduce their quality of life. These side effects also drive nonadherence, dose modifications, and ultimately treatment discontinuation. In fact, treatment intolerance is the leading cause of therapy discontinuation in the first two years of CML management. Adding to the complexity, current treatments—particularly ATP-competitive tyrosine kinase inhibitors (TKIs)—can affect not just the intended target but also unrelated biological pathways, causing off-target toxicity. This often leads to therapy switches, a strategy that increases both clinical and emotional burden without necessarily resolving the issue. A recent Indian analysis noted that nearly all CML patients report some form of low-grade side effect, many of which disrupt work and personal life but don’t qualify for hospitalization. As a result, patients feel caught in a difficult balance—managing a chronic illness while enduring ongoing discomfort or disruptions. The Case for Better-Tolerated, More Effective Therapies As the treatment landscape evolves, the need for therapies that not only offer deeper molecular responses but also better tolerability is becoming increasingly clear. Emerging therapies with novel mechanisms of action have begun to change the paradigm by offering comparable—or even superior—efficacy alongside fewer adverse events and lower discontinuation rates. In one international phase III trial, a newer therapy demonstrated a 74.1% MMR rate at 96 weeks, significantly higher than the 52.0% achieved by older therapies. It also showed a 54% lower risk of treatment discontinuation due to side effects, while nearly half of patients achieved MR4 and 30.9% achieved MR4.5, the deepest levels of response. These findings suggest that treatment no longer needs to be a trade-off between efficacy and day-to-day functioning. This shift is particularly important in the Indian context, where younger patients face the possibility of decades-long treatment. For them, the ability to tolerate therapy comfortably while still achieving long-term disease control is not a luxury—it’s a necessity. The Importance of Proactive Conversations Many patients continue older treatments unaware that newer, more tolerable options exist. This makes open doctor–patient conversations crucial—especially early in treatment. Patients should understand their goals, like DMR or TFR, and how their therapy aligns with them. Discussing side effects, lifestyle impact, and alternatives helps ensure care is not just effective, but sustainable and suited to their lives. While CML outcomes have improved, challenges remain—particularly for India’s younger patients. As treatment goals expand and better options emerge, the focus must shift from merely managing the disease to helping patients live well. The future of CML care lies in deeper responses, better tolerability, and enabling life beyond medication.

asianprimenews

India’s no. 1 EV takes safety to the next level – Nexon.ev Launched with ADAS

asianprimenews

‘Lala Lala Pai Jatti Ne Karayi Aa’ Simiran Kaur Dhadli is Back with a Banger

asianprimenews